Fidelity Australian Opportunities is an Managed Funds investment product that is benchmarked against ASX Index 200 Index and sits inside the Domestic Equity - Large Growth Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The Fidelity Australian Opportunities has Assets Under Management of 347.44 M with a management fee of 0.85%, a performance fee of 0.00% and a buy/sell spread fee of 0.4%.
From 1 October 2022, Casey McLean took over as Lead Portfolio Manager of the Fund and Clare Coleman as Co-portfolio Manager on the Fund. The Fund delivered positive returns but underperformed the index over the quarter. Stock selection in the materials, real estate and consumer staples sectors held back gains. Rising interest rates weighed on the holding in global property and infrastructure developer Lendlease Group.
Specialty biotherapeutics company CSL faced selling pressure along with the rest of the healthcare sector. Shares in sustainable materials producer Calix fell. Investor sentiment was weighed down by the Federal Government’s withdrawal of its grant funding plans for its carbon capture, use and storage (CUSS) programme. The underweight allocation to iron ore miners Rio Tinto held back relative gains. Its shares advanced inline with rising iron ore prices. IGO slid on retreating lithium prices. Its Nova nickel-copper mine has stopped operations after a fire at the power station. It may take several weeks to restore power. On a positive note, the lack of exposure to low-cost hard rock lithium miner Pilbara Minerals proved beneficial as its shares declined in line with lithium peers due to retreating lithium prices. Investors accumulated shares in gold miner Evolution Mining amid rising gold prices and a slowing rate of interest rate increases as indicated by the US Federal Reserve. Elsewhere, the position in leading commercial insurance broker Steadfast Group added value as its shares advanced. Investors cheered its assetlight and scalable business model, with limited underwriting risk bearing. The position in medical device company PolyNovo advanced after it reported record sales volumes, primarily driven by its US business.
Product Snapshot
Performance Review
Product Overview
Peer Comparison
Product Details